ALK+ Metastatic Non-Small Cell Lung Cancer: The Importance of Biomarker Testing

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Lung Cancer Initiative proudly participated in the GO2 Voices Summit held March 9–11, 2025, in Washington, DC.

Dr. Daniel J. Boffa discusses the link between smoking cessation and increase in survival for people who are active smokers and diagnosed with cancer.